Gilead Sciences logged a -0.7% change during today's evening session, and is now trading at a price of $80.61 per share. On average, analysts give it a target price of $85.47.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The large-cap company is based in the United States. Gilead Sciences currently returns an annual dividend yield of 3.6%.
Make Sure to Consider the Following Before Buying Gilead Sciences:
-
Gilead Sciences has moved -0.0% over the last year.
-
GILD has a forward P/E ratio of 11.8 based on its EPS guidance of 6.82.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 0.7%.
-
The company has a price to earnings growth (PEG) ratio of 3.05.
-
Its Price to Book (P/B) ratio is 4.75
Gilead Sciences Has None
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 9,512,000 | 586,000 | 8,926,000 | 6.98 |
| 2022 | 9,072,000 | 728,000 | 8,344,000 | -22.78 |
| 2021 | 11,384,000 | 579,000 | 10,805,000 | 43.72 |
| 2020 | 8,168,000 | 650,000 | 7,518,000 | -9.63 |
| 2019 | 9,144,000 | 825,000 | 8,319,000 | 11.28 |
| 2018 | 8,400,000 | 924,000 | 7,476,000 |
None
